cipla semaglutide strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy. This milestone launch is based on the recent ANDA approval obtained by Cipla's partner, Orbicular. Cipla India's Pharma Giants to Launch
Description
Just results
Supports Balanced Sugar Levels
As the interest in incretin-based therapies has risen substantially, we discuss how incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and GLP-1 receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) dual agonists, might improve reproductive function and could interact with the physiological metabolic changes ensuring a healthy pregnancy
In the presence of a mixture of gabazine (20 M) and tetrodotoxin (1 M), application GLP-1 significantly increased frequency, but not amplitude of miniature EPSCs via PKA signaling pathway
